Johnson & Johnson (JNJ) Scheduled to Post Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Tuesday, January 23rd. Analysts expect Johnson & Johnson to post earnings of $2.37 per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The company had revenue of $21.35 billion for the quarter, compared to the consensus estimate of $21 billion. On average, analysts expect Johnson & Johnson to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $162.39 on Tuesday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company's 50 day moving average is $155.04 and its 200 day moving average is $159.31. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. The company has a market cap of $390.92 billion, a PE ratio of 12.06, a price-to-earnings-growth ratio of 3.09 and a beta of 0.53.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 2.93%. Johnson & Johnson's dividend payout ratio (DPR) is presently 35.34%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. Wells Fargo & Company downgraded shares of Johnson & Johnson from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, January 9th. TheStreet cut shares of Johnson & Johnson from a "b" rating to a "c+" rating in a research note on Friday, November 17th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $174.00 to $171.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 18th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $178.00 price objective on shares of Johnson & Johnson in a research note on Friday, December 1st. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $168.94.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Jacobs Levy Equity Management Inc. increased its position in shares of Johnson & Johnson by 14.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,358 shares of the company's stock worth $679,000 after purchasing an additional 563 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $437,000. Delap Wealth Advisory LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $231,000. Phoenix Holdings Ltd. grew its position in Johnson & Johnson by 28.9% in the 3rd quarter. Phoenix Holdings Ltd. now owns 35,925 shares of the company's stock valued at $5,626,000 after acquiring an additional 8,049 shares in the last quarter. Finally, Tradewinds LLC. grew its position in Johnson & Johnson by 0.6% in the 2nd quarter. Tradewinds LLC. now owns 14,866 shares of the company's stock valued at $2,461,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 68.40% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.